Oligodendroglioma laboratory tests
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma laboratory tests |
|
Risk calculators and risk factors for Oligodendroglioma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Some patients with oligodendroglioma may have elevated protein and cell count with normal glucose and lactate on CSF analysis, which is usually suggestive of hydrocephalus. Immunohistochemistry of oligodendrogliomas shows positive staining for IDH1-R132H, ATRX, GFAP, SOX10, MAP2, S-100, EMA, Ki-67, NSE, synaptophysin, OLIG1, and OLIG2, and negativestaining for p53, and keratins.
Laboratory Findings
Lumbar Puncture
- Some patients with oligodendroglioma may have elevated protein and cell count with normal glucose and lactate on CSF analysis, which is usually suggestive of hydrocephalus.[1][2]
Immunohistochemical staining
- Oligodendrogliomas stain positive for:[3][4][5][6][7]
- IDH1-R132H (majority of cases)
- ATRX
- GFAP (positive in intermingled reactive astrocytes and minigemistocytes)
- SOX10
- MAP2
- S-100
- EMA
- Ki-67
- NSE
- Synaptophysin
- OLIG1
- OLIG2
- Oligodendrogliomas stain negative for:
References
- ↑ Stark AM, Hugo HH, Mehdorn HM, Knerlich-Lukoschus F (2009). "Acute Hydrocephalus due to Secondary Leptomeningeal Dissemination of an Anaplastic Oligodendroglioma". Case Rep Med. 2009: 370901. doi:10.1155/2009/370901. PMC 2797365. PMID 20052406.
- ↑ Li KW, Roonprapunt C, Lawson HC, Abbott IR, Wisoff J, Epstein F; et al. (2005). "Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas". Neurosurg Focus. 18 (6A): E2. PMID 16048288.
- ↑ IHC of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma
- ↑ Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV (2006). "[Immunohistochemistry in oligodendrogliomas]". Arq Neuropsiquiatr. 64 (1): 67–71. doi:/S0004-282X2006000100014 Check
|doi=value (help). PMID 16622556. - ↑ von Deimling, A; Hartmann, C (2005). "Oligodendrogliomas: Impact of molecular genetics on treatment". Neurology India. 53 (2): 140. doi:10.4103/0028-3886.16394. ISSN 0028-3886.
- ↑ Tanboon J, Williams EA, Louis DN (2016). "The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas". J Neuropathol Exp Neurol. 75 (1): 4–18. doi:10.1093/jnen/nlv009. PMID 26671986.
- ↑ Kato Y (2015). "Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas". Brain Tumor Pathol. 32 (1): 3–11. doi:10.1007/s10014-014-0202-4. PMID 25324168.